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Summary 
Vpre-B and k5 genes, respectively, encode V-like and C-like domains of a surrogate immuno- 
globulin light chain (~L). Such WL complex is expressed in early progenitor B  (pro-B) cells, 
before conventional immunoglobulin heavy (/~H) and light (L) chains are produced. We raised a 
wide panel of monoclonal antibodies (mAbs)  against  soluble recombinant Vpre-B proteins to 
study early events in httman B cell development. One of  these antibodies, B-MAD688, labeled sur- 
rogate Ig-complexes on the surface of btH- pro-B cell lines and normal bone marrow cells in im- 
munofluorescence assays. Immunoprecipitations using surface-labeled pro-B cells and B-MAD688 
mAb indicated that human ~L is associated with high molecular weight components homolo- 
gous to the surrogate heavy (~H)  chains described in mouse. Using B-MAD688  and SLC2 
mAbs, we were able to distinguish between XltH~L and btHWL complexes on the surface of 
human pro-B and later precursor, pre-B, cells. The finding of ~H~L  complexes in mouse and 
man lead us to hypothesize a role for ~H-containing receptors in B cell development. 
B 
-lymphocyte lineages are best defined by the expres- 
sion of their clonal receptors for antigen, the immuno- 
globulins  (Ig).  Hence, stages  in B  cell development path- 
ways are drawn in terms of the rearrangement state of Ig 
heavy (H) and light (L) chain genes. Rearrangement of H 
and L chain loci is markedly asynchronous, creating H+L  - 
or H-L  + intermediate receptors that might be implicated 
in further B cell differentiation (1-4). 
Whereas H  chains are not transported to the cell surface 
of mature B cells in the absence of L chains, this is not the 
case for B  cell progenitors (3--6). Best characterized is the 
association of the proteins encoded by the Vpre-B and h5 
genes that constitutes a surrogate L  (~L) complex, which 
replaces the  requirement for L in the  transport of Ig-like 
complexes to the cell surface  (5-7).  Mouse mutants  defi- 
cient in this ~L complex, created by targeted disruption of 
h5 gene, show a B  cell deficiency phenotype (8). Analyses 
of ~H  and ~L expression patterns and function are there- 
fore of  interest to know how B cell progenitors differentiate, 
and to study key molecular events in B cell development. 
Mouse models suggest that the ~L proteins couple first 
with ~H  on the surface of pro-B cells and later with con- 
ventional  p.H  chains  on  pre-B  cells  (3-5).  Similar  steps 
were proposed in man  (9),  although  none of the  mono- 
clonal antibodies (mAbs) reported yielded any immunopre- 
cipitate. Contrary to this hypothesis, other anti-human ~L 
mAb recognized p~H~L receptors in pre-B cells but failed 
to detect surface WH~L complexes in human pro-B cells, 
suggesting that ~L associates  only with p~H chains (6). 
We have produced human recombinant soluble Vpre-B 
molecules to characterize novel mAbs against XPL-contain- 
ing receptors. One of  these mAbs, B-MAD688, labels Vpre-B 
on  the  surface  of H-L-  pro-B  tumors  and  also  detects 
equivalent B cell progenitors [i.e., surface I~H-, CD10  bnght 
or CD19  au11] in human bone marrow.  We show that this 
mAb and the anti-h5 SLC2 mAb (6) can indeed discriminate 
whether ~L is associated with either @H~L or IxH~L Ig- 
like complexes on human pro-B and pre-B cell lines. The 
above  findings  suggest  a  B  cell  development  scheme. 
B-MAD688 mAb may facilitate the analyses of Ig-surrogate 
receptors, and their relationship with the growth and dif- 
ferentiation requirements of B cell progenitors in man. 
Materials and Methods 
Production of Human Soluble Vpre-B Proteins.  Plasmids pCEH- 
Vpre-B/mCK and pCEH-Vpre-B/h~l were constructed by inser- 
tion of a human  full-length Vpre-B DNA into two distinct ex- 
pression vectors containing either mouse CK or the hinge-CHz-CH 3 
domains of human IgG1 heavy chain,  respectively, kindly pro- 
vided by Dr. Karjalainen (10). The published sequence for the 
hVpre-B gene ends prematurely at a PstI site upstream to the ter- 
mination  codon due to the sequencing strategy. To allow for a 
full-length  cloning,  we  have  obtained  the  last 18  residues se- 
quence  from a  genomic Vpre-B  clone,  pHVPB-6  created  by 
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CACGTGTCCCT,  coding for Ala-Arg-Thr-Arg-Val-Pro amino 
acids. This information was then used to subclone Vpre-B DNA 
into the two expression vectors after generating the required com- 
plementary overhangs using oligonucleotides and the polymerase 
chain reaction to introduce EcoRI and HindlII restriction sites at 
the  5'  and  3'  ends,  respectively. The  overhang at  the  3'  primer 
also substitutes  the termination c0don for a splice donor site to create 
two  distinct  chimerical  Vpre-B  soluble  proteins,  fused  to  either 
mouse  CK  or human  "/1  domains  according  to  the  vector used. 
(Fig.  1 A). The primers were (sense) 5'-AGACTAGAATTCATG- 
Figure  1.  B-MAD688 mAb specifically recognizes soluble Vpre-B re- 
combinant  proteins.  A palette  of single-chain  chimeric proteins  was cre- 
ated using expression vectors that allow the generation  of fusion proteins 
through the splicing of their coding RNA messages (A). The expression 
vectors used (10) splice the genes of interest into either the human  Ig'y~ 
hinge-CH2-CH3 constant  domains  (h~/1, left) or the constant  domain  of 
mouse  K light  chain  (roCK, right). They contain  the adequate  sequences 
for the expression of the chimeric proteins in myeloma  cells (K-P, K-pro- 
moter; HCE, heavy chain core enhancer,  K-E, K-enhancer; polyadenyla- 
tion) and selection (amp, ampicillin; gpt, mycophenolic acid resistance). In 
B,  purified  recombinant  proteins  were  probed  in  several  independent 
Western  blots with either the B-MAD688 mAb (lanes I-4),  or antisera 
specific for the fusion  domains  (lanes 5 and  6,  anti-roCK;  lane  7,  anti- 
h%). The chimeric proteins were hVpre-B/mCK, lanes I and 5; mCD2/ 
roCK, lanes 2 and 6; hVpre-B/h3q, lanes 3 and 7; and hCD4/h3q, lane 4. 
Similar results were obtained  for the other B-MAD mAbs reported here. 
The selected anti-soluble  Vpre-B mAb do not bind in parallel assays to 
several other natural and recombinant  proteins  that  lack Vpre-B but in- 
clude  the  same  fusion  domains  (hlL-2/mCK and  hlL-2/h%  chimeras; 
and,  hlgG1 and  mlgG,K  monoclonals,  data  not  shown).  The  apparent 
molecular weights matched  the predicted  chimeric nature  of the purified 
proteins employed. 
TCCTGGGCTCCTGTC  and  (antisense)  5'-TGATACTTA- 
CCAGGGACACGTGTCCTGGCTGC. The constructs were se- 
quenced  to  confirm  the  fidelity  of the  inserts,  and  they  were 
transfected  into J558L  myeloma  cells  by  the  protoplast  fusion 
method  (10).  Mycophenolic  acid  resistant  clones were  selected 
and their supematants were checked for the production of fusion 
proteins  by  ELISA and  Western  assays, using  antiserum  against 
either roCK or the h',/1  domains.  The best producer clones were 
subcloned  four  times  to  stabilize  high  secretion  levels.  The 
hVpre-B/h',/1 and Vpre-B/mCK fusion proteins were purified af- 
ter  protein  A-sepharose  and  anti-mouse-CK-Affigel-10  affinity 
chromatographies from serum-flee culture supernatants. 
Identification  of B  Cell Hybridomas  that  Produce Antibodies  Specific 
against Soluble  Human  Vpre-B.  BALB/c  female  mice  were  im- 
munized  four times  with  purified  hVpre-B/hyl  protein  (5  Ixg/ 
mouse/d)  in  the  rear  left footpad.  The  antigen  administered  at 
day 0 was emulsified in complete Freund adjuvant, and in PBS for 
days  3,  7,  and  14.  Samples from tail blood were  monitored for 
anti-hVpre-B/mCK activity. The left popliteal lymph node from 
the best responder was obtained 24 h  after the final boost, a single 
cell suspension was prepared, and the lymphocytes fused to the X63 
myeloma using the K6hler and Milstein's protocol.  Supernatants 
from the hybridoma clones arising from the fusion were tested for 
anti-Vpre-B  activity using ELISA and Western  assays,  including 
hVpre-B/mCK and hVpre-B/h'y1  proteins.  The mAb specificity 
was  established  using in parallel  a broad  palette  of recombinant 
and  natural  proteins  containing the  fusion domains.  The palette 
included  hlL-2/mCK,  mCD2/mCK,  hlL-2/hyl,  hCD4/hyl, 
pure human IgG1 from a myeloma patient and mouse CR or CK- 
containing monoclonals,  mAbs  recognizing the  Vpre-B  domain 
in the two  chimeric soluble proteins,  that  did not cross-react to 
mouse CK or the human  lgG1  domain were selected for further 
immunofluorescence screening of binding to  surface Vpre-B  on 
several human cells.  Four mAbs which reacted specifically and in 
a  dose-dependent  fashion  on  ELISA plates  coated  with  the  re- 
combinant Vpre-B proteins are characterized here. 
Human  Cells.  We  used  cell  lines  that  represented  different 
stages  in  the  development of the  B  cell lineage.  They  included 
lkEH  and  207  pro-B  cells,  697  and  Nalm-6  pre-B  cells,  and 
Daudi (IgM, K), ILamos (IgM, k), andJY  (IgG, K) mature B cells 
(6).  Other  hematopoietic  and  non-hemopoietic  cell  lines  in- 
cluded were K562, Jurkat,  U937, and HeLa. The origins and the 
state of Ig gene loci of the cell lines used are listed elsewhere (6, 
see  Table  I).  All cells were  maintained  in  RPMI-1640  supple- 
mented  with  2  mM  L-glutamine,  10%  FCS  (BioWhittaker, 
Verviers, B) and 5  ￿  10  .5 M  2-ME (Fluka, Buchs, CH). Samples 
from bone  marrow  were  obtained  after  informed  consent  from 
healthy donors involved in allogeneic transplants. 
Antibodies and Immunofluorescence  Assays.  Mouse mAb were DA4.4 
(IgG1,K)  specific  for  human  IxH  chain,  SLC1  (IgG,  K),  SLC2 
(IgM,  K), and SLC3 (IgM,  K) specific for human ~L  chain com- 
ponents  (6).  These were a kind gift of Dr.  Lassoued.  CD19  and 
CD10 mAb directly conjugated with FITC were purchased from 
Becton-Dickinson  (MountainView,  CA).  B-MAD  mAbs  re- 
ported herein  (IgM,  K) were purified by size-exclusion chroma- 
tography, and DA4.4 was purified by ProtA columns. They were 
biotin-labeled  using  standard  protocols.  In  three-color  studies 
with  biotinylated-DA4.4  we  used  streptavidin-TC  (CALTAG 
Labs., South San Francisco, CA). For immunofluorescence stain- 
ing,  cells (1.5  ￿  10S/test)  were incubated with  1  Ixg of purified 
mAb  or 50  ~1 of culture  supernatant  in 96-well conical bottom 
plates at 4~  for 20 min. They were then washed three times with 
PBS-gelatin. Where necessary,  they were incubated  with the ap- 
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Human Cell  Lines 
Ig gene Re-  mAb 
arrangement  reactivity 
Cell Type  Cell Line  H  L  688  1112  176  792 
Pro B  (0dHt~L)  1KEH  N  N  +  + 
207  N  N  + 
Pre B (Ht~L)  697  Y  N  +  +  +  + 
Nalm6  Y  N  +  +  +  + 
Mature B (HL)  Ramos (p,h)  Y  Y  - 
Daudi(lxK)  Y  Y  -- 
JY (yK)  Y  Y  - 
T  Jurkat  N  N  - 
Erythroleukemia K562  N  N  - 
Promyelocytic  U937  N  N  - 
Epithelial  HeLa  N  N  - 
Reactivity was determined  by cell surface immunofluorescence  as de- 
scribed in Materials and Methods.  Y, functional rearrangement/protein 
available; N, no functional rearrangement/no protein. 
propriate second layer and washed three additional times. In the 
epitope competition assays, the cells were incubated in criss-cross 
combinations with 10 I~g/test of the competing mAb (unlabeled 
and purified) for 20 min. This was followed by 1 p~g/test of the 
relevant mAb (which was biotinated or displayed a distinct iso- 
type) for another 20 min. The unbound mAbs were removed by 
three washes with PBS and the bound relevant mAbs were re- 
vealed with the adequate second layer (streptavidin-PE for bioti- 
nated-IgMs  and  anti-IgG-FITC for  IgGs  mAbs,  respectively). 
The binding was quantitated using both XL or FACScan  |  cytoflu- 
ofimeters (Coulter,  Hialeah, FL,  and Becton-Dickinson, respec- 
tively). Flow cytometry was  rendered quantitative using QIFI- 
KIT calibrator beads, which bear known amounts of an antigen 
(5,200  to 480,000)  and a FITC-labeled antibody specific for the 
antigen (BIOCYTEX, Marseille, France). 
Surface-labeling of Cells, Immunoprecipitation, and Western Experi- 
ments.  Cells in culture (10-20  ￿  106) were washed five times 
with  cold  washing buffer  (PBS  +  1  mM  MgC12  +  0.1  mM 
CaC12). The cells were then incubated with 0.5 mg/ml of Sulfo- 
NHS-Biotin  (Pierce Chem.  Co.,  Rockford,  IL)  for 30  min  at 
4~  on  a  turning wheel.  Biotination was stopped washing five 
times with  washing buffer.  Aliquots of 10  v biotin-labeled cells 
were lysed in 1 rnl of 1% NP40, 150 mM NaC1,  1 mM PMSF, 20 
mM iodoacetamide and 20 mM Tris, pH 7.5, for 30 rain on ice. 
Cell  lysates  were  precleared four  times  with  Affigel-10 beads 
(BIO-RAD, UK)  preincubated with  5%  nonfat dry milk. Pre- 
cleared samples were incubated overnight at 4~  with  10  p,1 of 
the indicated antibodies coupled to Affigel-10 beads (1  mg/rnl). 
lmmunoprecipitates were washed four times with lysis buffer plus 
0.5 M NaC1 and twice with lysis buffer, suspended in 10 ~1 of re- 
ducing loading buffer, boiled for 2  min and submitted to SDS- 
PAGE. The gels were Western-blotted onto nitrocellulose mem- 
branes,  using a Mini-Protean unit following the manufacturer's 
recomendations (BIO-RAD). After blocking with 5% nonfat dry 
milk in PBST  (PBS  plus 0.1% Tween 20)  the membranes were 
incubated with a 1:5,000 dilution ofstreptavidin-HRPO (South- 
ern Biotechnology, Birmingham,  AL)  in  PBST  for  30  rain  at 
room temperature, and washed three times with PBST. Surface- 
biotinated proteins were revealed using the  chemiluminescence 
ECL  kit  (Amersham,  UK)  after  1-5-s  exposures to  X-OMAT 
fihns (Kodak). 
Results  and Discussion 
Production of Human  Soluble Vpre-B Proteins and Isolation of 
Hybridoma Clones that Produce Specific Antibodies to  Vpre-B, 
To  raise  anti-human  Vpre-B  specific  antibodies we  pro- 
duced  two  distinct soluble Vpre-B  proteins.  Vpre-B  was 
fused  to  Ig-constant  domains  to  create  hVpre-B/h2q  or 
hVpre-B/mCK recombinant single-chain molecules (Fig. 1 
A).  It is similar to  the  strategy we  have  used to  map  the 
subunit specificity of mAbs against the human  CD3  trans- 
duction subunits of the T  cell receptor for antigen (12). 
Using purified hVpre-B/h%  protein as immunogen,  we 
produced a panel of mAbs that indeed recognizes Vpre-B, 
as they specifically bind to the hVpre-B/h%  and hVpre-B/ 
roCK  protein  chimeras,  as  demonstrated  in  ELISA  and 
Western assays (see Materials and Methods and Fig. 1 B). 
We next screened the panel of anti-soluble Vpre-B mAbs 
for binding to Vpre-B on the surface of B  cell precursors. 
Four mAbs were selected and further characterized  in im- 
munofluorescence  and  quantitative flow-cytometry assays. 
These anti-Vpre-B mAb, the B-MAD  176,  688,  792,  and 
1112 mAbs, label precursors of B  lymphocytes but neither 
mature  B  cell lines nor cells from  other lineages (Table  1 
and Fig. 2 A). 
Interestingly, the analysis of the staining patterns of two 
pro-B (REH and 207 IgH-L-  cells) and two pre-B (Nalm6 
and  697  IgH+L -  cells) human  lines revealed that the sur- 
face expression of Vpre-B  emerges already in  ~H-  pro-B 
cells, as shown using the B-MAD688 mAb (Fig. 2 A). The 
SLC1  and  SLC2 mAbs rendered a  distinct pattern  (Fig. 2 
A), which is the reported pre-B cell-confined staining (6). 
In this regard, the ability of anti-soluble Vpre-B  mAbs to 
bind their ligand on  the surface of both pro-B and pre-B 
cells was rare, whereas the pre-B cell-restricted cluster (i.e., 
SLCs (6), B-MAD176 or 792) is large and appears immuno- 
dominant.  Other  specificities however  occurred,  like  the 
B-MAD1112  mAb  that  binds  to  the  pre-B  cells and  the 
REH  pro-B cell but not to the 207 pro-B cell (Fig. 2 A). 
Vpre-B  Is  Expressed on  the  Surface of B  Cell  Progenitors 
from Normal Human Bone Marrow.  We  examined whether 
B-MAD688  mAb  might  be  a  tool  for  fluorescence-acti- 
vated cell-sorting of equivalent Vpre-B + precursor popula- 
tions from bone marrow. 
Two-color  flow  cytometry  analyses  showed  that 
B-MAD688  mAh labels well discrete populations of bone 
marrow  cells which  are either CD10 +  or CD19 +  (Fig.  2 
B).  As B  cell precursors mature  they lose CD10  and gain 
CD19  (9).  In  this regard,  the  Vpre-B +  subsets were  pre- 
dominantly  CD10 b'ight  and  CD19 dull  cells.  Triple-color 
studies showed that Vpre-B expression emerges in cells that 
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Figure  2.  FACS  TM  analyses of Vpre-B/k5 surrogate L 
(~L) chains expressed on the surface of human pro- and 
pre-B cell lines, and normal bone marrow cells as detected 
by specific mAbs. In A, pro-B (207 and REH), pre-B (697 
and Nalm6) and mature B (R.amos and JY) cell lines were 
incubated  first with either  control  mAb, soluble Vpre-B 
specific mAbs B-MAD688 and  1112, ~L-specific  mAb 
SLC1 or k5-specific mAb SLC2 (6), and then with HTC- 
conjugated anti-mouse  Ig antiserum. Immunofluorescence 
was quantitated on an EPICS XL  TM analyzer. Histograms 
depict the fluorescence distribution curves in a four decade 
logarithmic scale. In the case of control staining more than 
99% of cells were below the C  (right)  statistic analysis bar. 
SLC3 rendered similar results to SLC1 and 2 mAb (not de- 
picted in the sake of clarity). In/3, Vpre-B-bearing cells in 
normal  bone  marrow  were  phenotyped  by  two-color 
flowcytometry  in a  FACScan  TM  analyzer. The lymphoid 
population  was identified by its light scatter features and 
gated for these analyses. Cells were  stained with control 
mAbs or anti-soluble Vpre-B  mAb B-MAD688  (using an 
orange-red  PEqabel)  and  either  CD10  or  CD19  mAb 
(green FITC-labeled).  In control stainings more than 99% 
of the cells were in the lowerqeft quadrant defined by the 
crossed statistics bars. In the dot plots depicted, 36% of the 
CD10  § cells  (which are 3.5% of  total) and 29% of  the CD19 + 
cells (which are 8% of total) bound the B-MAD688 mAb. 
lack surface  ~H  and are CD34 §  These cells are the major 
Vpre-B §  bone  marrow  subset  detected  (i.e.,  3/4  of the 
688 +  cells  express  CD34).  No  CD3 +,  CD14 +,  CD16 +, 
CD33 +,  or  CD56 +  cells  expressed  Vpre-B  (not  shown). 
Thus,  in  normal  cells,  surface  expression  of  Vpre-B 
emerges early in B  cell development. 
SugCace Vpre-B Is Associated with Surrogate-Heavy  Chains (~t/H) 
in Human Pro-B Cells.  The  existence  of human  ~H~L 
complexes has remained elusive due to the lack of antibod- 
ies able to  immunoprecipitate surface ~L  before  txH  chain 
expression (6,  9).  We sought to reassess this issue using the 
B-MAD688  mAb.  Irranunoprecipitations were  carried out 
after surface biotin-labeling of lines arrested at distinct stages 
in B  cell  development.  The  precipitates  were  resolved by 
SDS-PAGE, Western blot and chemiluminescence. 
Interestingly, the anti-Vpre-B B-MAD688 mAb does not 
co-precipitate  txH  among  ~L-associated  proteins,  but 
other components of higher molecular weight, from pre-B 
and  pro-B  cell  lysates  (Fig.  3).  A  major band  of 125-kD 
substitutes for the  absent tall in the pro-B  line 1KEH,  and 
was consistently detected in all nine experiments performed. 
Other  weaker  bands  (roughly  p200,  pl00,  and  p70-40) 
were  evident upon longer exposure  in some  experiments. 
In  contrast,  analyses  using  the  SLC2  mAb  revealed  the 
known  subset  of surface  XtrL that  coprecipitates  with  the 
surface  b~H but does  not associate with tlrH.  The  identity 
of  conventional  txH  was  readily  determined  using  the 
DA4.4  anti-I~ mAb in parallel tracks.  Both  anti-~L mAbs 
did not recognize mature B  cells (Fig. 3).  The proteins co- 
precipitated by B-MAD688  mAb resemble the ~H  chains 
found by Karasuyama, Rolink, and Melchers associated to 
Figure  3.  Vpre-B/k5 surrogate L (XlrL) chains are associated to both 
conventional (p~H) and surrogate  (XI~H) heavy chains on the surface of 
B-cell precursors in irmnunoprecipitation assays. Cells representative of  dis- 
tinct stages of B-lymphocyte  development,  pre-B  (697), pro-B  (REH) 
and mature B (Ramos) cell  lines, were surface labeled with biotin and lysed 
in 1% NP40 lysis buffer. Detergent-soluble  lysates were reacted with ei- 
ther anti-&H mAb DA4.4 (lanes 1), anti-VpreB mAb B-MAD688 (lanes 
2) or anti-k5 mAb SLC2 (lanes 3), immunoprecipitates were resolved by 
10% SDS-PAGE  under reducing conditions,  Western  blotted,  and re- 
vealed by chemiluminescence.  Open arrowheads point to conventional 
heavy (/4) and light (L) chains, filled arrowheads point to surrogate heavy 
chains (~H). Apparent molecular mass, in kD, were estimated using a set 
of biotin-conjugated  protein standards. 
2696  Surface Vpre-B in Human Pro-B Cells ￿9 L in mouse ~H-  pro-B cells  (5,  7,  13).  The finding of 
p125 as the major ~H  component parallels an independent 
report also using mouse pro-B tumor hnes (14). 
Human Vpre-B is not readily available during selective, 
vectorial labeling of the  cell surface proteins  using either 
125I (6) or biotin. Aliquots of pro-B and pre-B cell lysates 
were precipitated with B-MAD688 mAb, submitted to elec- 
trophoresis and revealed by Western blot using B-MAD688 
mAb. The anti-Vpre-B antibody reacted with a 18-kD band 
(i.e., native Vpre-B size), but not with the 125-kD protein 
or other higher molecular weight bands (not shown). 
We studied whether anti-Vpre-B mAbs B-MAD688 and 
1112, and SLC mAbs recognize different epitopes on surface 
￿9 L  chains  from pre-B  cells,  as  suggested  by the  immu- 
nofluorescence clusters and immunoprecipitation results. The 
SLC1, SLC2, and SLC3 mAb epitopes are overlapping (6). 
Our  results  of criss-cross  competition analyses  evidenced 
that  SLC1  showed a  clear but partial  (30%)  competition 
with B-MAD1112 mAb, again indicative of overlapping or 
neighbor,  but  not  identical,  epitopes.  This  competition 
pattern  was  distinct  to  the  observed for the  B-MAD688 
mAb  and for the anti-p~ DA4.4  mAb,  that did not show 
any cross-blocking of their binding by the mAb tested (data 
not shown). 
Since  B-MAD688  mAb  recognizes  VpreB  and  SLC2 
mAb binds to k5 (6), it is not surprising that they could de- 
fine distinct epitopes in human ~L.  Our results  however 
underscore  that  these  two  mAbs  discriminate  among 
￿9 H~L  and  ~H~L  due  to  a  differential  display  of XPL 
epitopes in those complexes. As B-MAD688 mAb recog- 
nizes only the former receptor, it defines a novel anti-~L 
specificity (6, 9, 13). 
Two other reactivities were established in the mouse (5, 
13).  First,  mAbs that selectively bind to ~L when assem- 
bled in p~H~L complexes (i.e., do not detect ~H~L  com- 
plex although may recognize free Vpre-B or k5, as shown 
before for SLC mAbs in man [6]). Second, mAbs that rec- 
ognize ￿9 L subunits but do not discriminate whether Vpre-B 
and k5 are associated  to ~H  or p~H chains;  perhaps similar 
to some anti-~L mAbs in man (9). The staining pattern of 
B-MAD  1112 mAb is yet difficult to interpret because the 
mAb  does not render immunoprecipitates from pro-B or 
pre-B cell lysates. 
Light and Enigmas on the Use of lg-Surrogate Complexes and 
on  the Definition  of Human  B  Cell  Developmental  Pathways. 
Our results indicate that Vpre-B is a subunit shared by two 
Ig-like surface complexes, homologous in mouse and man. 
First,  it emerges in ~HXPL receptors on pro-B cells.  Sec- 
ond, it is component of ~H~L complexes on pre-B cells. 
The existence of ~H  has been controversial in man (6, 9). 
The fact that SLC2 mAb binds to surface ~L chains only 
when they are associated with p~H chains might explain why 
￿9 H~L complexes escaped detection by other authors (6). 
The emphasis in the analyses  of Ig-surrogate chains has 
been  placed  on  human  pre-B  cells  that  are  H+L  -,  on 
which ~H~L pre-B receptors would play a developmental 
role (6, 9).  Less attention was payed to a reciprocal H-L  + 
human pre-B cell pathway, defined by Kubagawa et al. (1). 
The finding of surface ~H  chains in man opens the possi- 
bility that ~H  may assemble with L into putative surface 
￿9 HL receptors on  H-L  +  pre-B  cells  in  the  Kubagawa's 
pathway. By analogy to the major pathway (15,  16), ~HL 
pre-B receptors could serve to sustain the rare cychng pre-B 
cells that bear only productive V-J-C  L rearrangements. The 
￿9 HL receptors might allehcaly exclude the L loci in pre-B 
cells at the minority pathway, while fxH loci attempts re- 
combination and surface btH can replace ~H  in the suc- 
cessful B cell progeny. Two B cell differentiation pathways 
also occur in mouse but only the ~L-containing pre-B re- 
ceptors  were  considered  in  the  schemes  (2,  3).  Other 
authors pointed that a WL-independent pathway predomi- 
nates  early in  ontogeny when B-la/CD5 +  cells preferen- 
tially develop (17).  To test whether the ~L-independent 
pathway uses ~H  pre-B receptors requires the availability 
of  probes for WH chain components, especially considering 
that H-L  + cells are infrequent (2, 18). 
Another  intriguing  observation,  divergent  from  pre- 
vious  models  (2-4,  6,  9),  concerns  the  coexpression  of 
WH~L and  IxH~L surrogate receptors on pre-B cell tu- 
mors. We could not readily detect a similar B-MAD688 bright, 
SLC1 b'ight bone marrow subpopulation (not shown). Simi- 
larly a  "transition"  IxH~L  +,  IxHKL +  step  was  shown  in 
human  tumors, but its  in vivo counterpart was  undetect- 
able to the same mAb (6).  It is worthy of note that, using 
similar methods in man (6) or mouse (7, 13), faint levels of 
surface IxH were reported in normal p~H~L  + pre-B cells. 
Also, ~H~L + cells are readily shown ex vivo, whereas a 
majority  of cytoplasmic  IxH  +  cells  lack  surface  IxH~L 
complexes (4, 6, 7). A sensitive analysis of surrogate chains 
expression and immunoglobuhn  loci status  in  single  cells 
will be required to order the B cell development steps. 
In  summary,  we  raised  mAbs  against  soluble  human 
Vpre-B.  We  show that Vpre-B is  expressed associated to 
~H  chains  on the surface of pro-B cell tumors,  and that 
the  Vpre-B+/~H~L  complex  detected  by  B-MAD688 
mAb is a good marker to identify early B cell progenitors in 
human bone marrow. We propose that ~H-containing re- 
ceptors might also participate in a second class of~HL pre-B 
receptors devoted to drive the development of rare precur- 
sors that rearrange L-chains first. 
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